标题
Drug repositioning in the treatment of malaria and TB
作者
关键词
-
出版物
Future Medicinal Chemistry
Volume 3, Issue 11, Pages 1413-1426
出版商
Future Science, LTD
发表日期
2011-09-01
DOI
10.4155/fmc.11.95
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Effect of Meropenem against Multidrug-ResistantMycobacterium tuberculosis
- (2014) A.Y. Coban et al. JOURNAL OF CHEMOTHERAPY
- A phase I trial to evaluate the safety and pharmacokinetics of low-dose methotrexate as an anti-malarial drug in Kenyan adult healthy volunteers
- (2011) Roma Chilengi et al. MALARIA JOURNAL
- Update on genetic markers of quinine resistance in Plasmodium falciparum
- (2011) John Okombo et al. MOLECULAR AND BIOCHEMICAL PARASITOLOGY
- Antibiotics in Malaria Therapy and their Effect on the Parasite Apicoplast
- (2010) G. Pradel et al. CURRENT MOLECULAR MEDICINE
- Drugs in Development for Tuberculosis
- (2010) Ann M. Ginsberg DRUGS
- Synthesis and antitubercular activity of new mefloquine-oxazolidine derivatives
- (2010) Raoni S.B. Gonçalves et al. EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY
- Intermittent preventive treatment against malaria: an update
- (2010) Roly D Gosling et al. Expert Review of Anti-Infective Therapy
- The nitroimidazooxazines (PA-824 and analogs): structure–activity relationship and mechanistic studies
- (2010) William A Denny et al. Future Medicinal Chemistry
- Thioridazine cures extensively drug-resistant tuberculosis (XDR-TB) and the need for global trials is now!
- (2010) Leonard Amaral et al. INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS
- Azithromycin Combination Therapy for the Treatment of Uncomplicated Falciparum Malaria in Bangladesh: An Open‐Label Randomized, Controlled Clinical Trial
- (2010) Kamala Thriemer et al. JOURNAL OF INFECTIOUS DISEASES
- Global tuberculosis drug development pipeline: the need and the reality
- (2010) Zhenkun Ma et al. LANCET
- Artesunate versus quinine in the treatment of severe falciparum malaria in African children (AQUAMAT): an open-label, randomised trial
- (2010) Arjen M Dondorp et al. LANCET
- Best drug treatment for multidrug-resistant and extensively drug-resistant tuberculosis
- (2010) José A Caminero et al. LANCET INFECTIOUS DISEASES
- Conformationally-constrained indeno[2,1-c]quinolines – a new class of anti-mycobacterial agents
- (2010) Ram Shankar Upadhayaya et al. ORGANIC & BIOMOLECULAR CHEMISTRY
- Synthesis and structure of azole-fused indeno[2,1-c]quinolines and their anti-mycobacterial properties
- (2010) Ram Shankar Upadhayaya et al. ORGANIC & BIOMOLECULAR CHEMISTRY
- The evolution, metabolism and functions of the apicoplast
- (2010) L. Lim et al. PHILOSOPHICAL TRANSACTIONS OF THE ROYAL SOCIETY B-BIOLOGICAL SCIENCES
- The Global Fight Against HIV/AIDS, Tuberculosis, and Malaria
- (2009) Marco Vitoria et al. AMERICAN JOURNAL OF CLINICAL PATHOLOGY
- Substitution of Moxifloxacin for Isoniazid during Intensive Phase Treatment of Pulmonary Tuberculosis
- (2009) Susan E. Dorman et al. AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE
- Addition of PNU-100480 to First-Line Drugs Shortens the Time Needed to Cure Murine Tuberculosis
- (2009) Kathy N. Williams et al. AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE
- In Vitro Activity of Antifolate and Polymorphism in Dihydrofolate Reductase of Plasmodium falciparum Isolates from the Kenyan Coast: Emergence of Parasites with Ile-164-Leu Mutation
- (2009) S. M. Kiara et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Meropenem-Clavulanate: A New Strategy for the Treatment of Tuberculosis?
- (2009) Ulrike Holzgrabe ChemMedChem
- Beta-lactams and Beta-lactamase-inhibitors in current- or potential-clinical practice: A comprehensive update
- (2009) M. Shahid et al. CRITICAL REVIEWS IN MICROBIOLOGY
- Drug repositioning summit: Finding new routes to success
- (2009) C. Campàs DRUG NEWS & PERSPECTIVES
- Long-term Methotrexate for Crohnʼs Disease
- (2009) Eugeni Domènech et al. JOURNAL OF CLINICAL GASTROENTEROLOGY
- Moxifloxacin versus ethambutol in the initial treatment of tuberculosis: a double-blind, randomised, controlled phase II trial
- (2009) Marcus B Conde et al. LANCET
- Artemisinin Resistance inPlasmodium falciparumMalaria
- (2009) Arjen M. Dondorp et al. NEW ENGLAND JOURNAL OF MEDICINE
- Meropenem-Clavulanate Is Effective Against Extensively Drug-Resistant Mycobacterium tuberculosis
- (2009) J.-E. Hugonnet et al. SCIENCE
- New anti-tuberculosis agents amongst known drugs
- (2009) Kathryn E.A. Lougheed et al. TUBERCULOSIS
- Drug Discovery Using Chemical Systems Biology: Repositioning the Safe Medicine Comtan to Treat Multi-Drug and Extensively Drug Resistant Tuberculosis
- (2009) Sarah L. Kinnings et al. PLoS Computational Biology
- Early and Extended Early Bactericidal Activity of Linezolid in Pulmonary Tuberculosis
- (2008) Reynaldo Dietze et al. AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE
- Promising Antituberculosis Activity of the Oxazolidinone PNU-100480 Relative to That of Linezolid in a Murine Model
- (2008) K. N. Williams et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Role of Methotrexate in the Treatment of Chronic Cholestatic Disorders
- (2008) Kerri Novak et al. Clinics in Liver Disease
- The Plastid-Like Organelle of Apicomplexan Parasites as Drug Target
- (2008) J. Wiesner et al. CURRENT PHARMACEUTICAL DESIGN
- HIV Protease Inhibitors Inhibit the Development of Preerythrocytic-StagePlasmodiumParasites
- (2008) Charlotte V. Hobbs et al. JOURNAL OF INFECTIOUS DISEASES
- Azithromycin-chloroquine and the intermittent preventive treatment of malaria in pregnancy
- (2008) R Matthew Chico et al. MALARIA JOURNAL
- High Risk of Severe Anaemia after Chlorproguanil-Dapsone+Artesunate Antimalarial Treatment in Patients with G6PD (A-) Deficiency
- (2008) Caterina I. Fanello et al. PLoS One
- The protonmotive force is required for maintaining ATP homeostasis and viability of hypoxic, nonreplicating Mycobacterium tuberculosis
- (2008) S. P. S. Rao et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started